<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Goubau D</submitter><funding>NIAID NIH HHS</funding><pagination>527-40</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC2773157</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>39(2)</volume><pubmed_abstract>The immunoregulatory transcriptional modulators - IFN-regulatory factor (IRF)-3 and IRF-7 - possess similar structural features but distinct gene-regulatory potentials. For example, adenovirus-mediated transduction of the constitutively active form of IRF-3 triggered cell death in primary human MPhi, whereas expression of active IRF-7 induced a strong anti-tumoral activity in vitro. To further characterize target genes involved in these distinct cellular responses, transcriptional profiles of active IRF-3- or IRF-7-transduced primary human MPhi were compared and used to direct further mechanistic studies. The pro-apoptotic BH3-only protein Noxa was identified as a primary IRF-3 target gene and an essential regulator of IRF-3, dsRNA and vesicular stomatitis virus-induced cell death. The critical role of IRF-7 and type I IFN production in increasing the immunostimulatory capacity of MPhi was also evaluated; IRF-7 increased the expression of a broad range of IFN-stimulated genes including immunomodulatory cytokines and genes involved in antigen processing and presentation. Furthermore, active IRF-7 augmented the cross-presentation capacity and tumoricidal activity of MPhi and led to an anti-tumor response against the B16 melanoma model in vivo. Altogether, these data further highlight the respective functions of IRF-3 and IRF-7 to program apoptotic, immune and anti-tumor responses.</pubmed_abstract><journal>European journal of immunology</journal><pubmed_title>Transcriptional re-programming of primary macrophages reveals distinct apoptotic and anti-tumoral functions of IRF-3 and IRF-7.</pubmed_title><pmcid>PMC2773157</pmcid><funding_grant_id>R01 AI068133</funding_grant_id><funding_grant_id>R01 AI068133-09</funding_grant_id><funding_grant_id>R01 AI068133-07A1</funding_grant_id><funding_grant_id>R01 AI068133-08</funding_grant_id><pubmed_authors>Hernandez E</pubmed_authors><pubmed_authors>Hiscott J</pubmed_authors><pubmed_authors>Mesplede T</pubmed_authors><pubmed_authors>Lin R</pubmed_authors><pubmed_authors>Leaman D</pubmed_authors><pubmed_authors>Solis M</pubmed_authors><pubmed_authors>Goubau D</pubmed_authors><pubmed_authors>Romieu-Mourez R</pubmed_authors></additional><is_claimable>false</is_claimable><name>Transcriptional re-programming of primary macrophages reveals distinct apoptotic and anti-tumoral functions of IRF-3 and IRF-7.</name><description>The immunoregulatory transcriptional modulators - IFN-regulatory factor (IRF)-3 and IRF-7 - possess similar structural features but distinct gene-regulatory potentials. For example, adenovirus-mediated transduction of the constitutively active form of IRF-3 triggered cell death in primary human MPhi, whereas expression of active IRF-7 induced a strong anti-tumoral activity in vitro. To further characterize target genes involved in these distinct cellular responses, transcriptional profiles of active IRF-3- or IRF-7-transduced primary human MPhi were compared and used to direct further mechanistic studies. The pro-apoptotic BH3-only protein Noxa was identified as a primary IRF-3 target gene and an essential regulator of IRF-3, dsRNA and vesicular stomatitis virus-induced cell death. The critical role of IRF-7 and type I IFN production in increasing the immunostimulatory capacity of MPhi was also evaluated; IRF-7 increased the expression of a broad range of IFN-stimulated genes including immunomodulatory cytokines and genes involved in antigen processing and presentation. Furthermore, active IRF-7 augmented the cross-presentation capacity and tumoricidal activity of MPhi and led to an anti-tumor response against the B16 melanoma model in vivo. Altogether, these data further highlight the respective functions of IRF-3 and IRF-7 to program apoptotic, immune and anti-tumor responses.</description><dates><release>2009-01-01T00:00:00Z</release><publication>2009 Feb</publication><modification>2020-11-07T09:22:08Z</modification><creation>2019-03-27T00:26:22Z</creation></dates><accession>S-EPMC2773157</accession><cross_references><pubmed>19152337</pubmed><doi>10.1002/eji.200838832</doi></cross_references></HashMap>